* Calithera Biosciences Inc CALA.OQ CALA.O is expected
to show
no change in quarterly revenue when it reports results on May 4
(estimated).
* Refinitiv's mean analyst estimate for Calithera
Biosciences Inc
is for a loss of 18 cents per share. For the same quarter last
year, the company reported a loss of 28 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Calithera
Biosciences Inc is $2.5, above its last closing price
of $0.25.
* Previous quarterly performance (using preferred earnings
measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Dec. 31 2021 -0.27 -0.24 -0.24 Met 0
Sep. 30 2021 -0.22 -0.23 -0.15 Beat 34.2
Jun. 30 2021 -0.24 -0.24 -0.19 Beat 20.9
Mar. 31 2021 -0.27 -0.28 -0.28 Met -1.4
Dec. -0.33 -0.32 -0.32 Met 1.2
31 2020
Sep. 30 2020 -0.31 -0.31 -0.32 Missed -3.1
Jun. 30 2020 -0.33 -0.33 -0.29 Beat 13.3
Mar. 31 2020 -0.36 -0.36 -0.38 Missed -5.8
This summary was machine generated May 3 at 01:22 GMT. All
figures in US dollars unless otherwise stated